Related Experiment Video
Updated: Jun 9, 2026
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Impact of Biopharmaceutics Classification System-based biowaivers
Jack A Cook1, Barbara M Davit, James E Polli
1Department of Clinical Pharmacology, Specialty Care Business Unit, Pfizer Inc., New London, CT, USA.
Molecular Pharmaceutics
|August 26, 2010
Summary
Biopharmaceutics Classification System (BCS) biowaivers for Class I drugs save millions annually. Expanding biowaivers to Class III drugs could offer substantial additional economic relief and reduce unnecessary clinical testing.
Area of Science:
- Pharmacokinetics and Drug Development
- Regulatory Science
- Health Economics
Background:
- The Biopharmaceutics Classification System (BCS) categorizes drugs based on solubility and permeability, influencing bioequivalence testing requirements.
- Biowaivers, enabled by BCS, reduce the need for in vivo studies, benefiting patients and healthcare systems.
- Current biowaiver applications primarily focus on BCS Class I drugs, with scientific consensus supporting potential expansion to Class III.
Purpose of the Study:
- To quantify the economic impact of granting biowaivers for BCS Class I drugs.
- To estimate the potential economic benefits of extending biowaivers to BCS Class III drugs.
- To analyze the influence of highly variable drugs (HVDs) on biowaiver cost savings.
Main Methods:
- Analysis of drug distribution across the four BCS classes.
- Review of the number of in vivo bioequivalence studies conducted over a five-year period.
- Inclusion of factors related to highly variable drugs (HVDs) in economic estimations.
Main Results:
- BCS Class I non-HVDs constitute 26% of drugs, and HVDs represent 7%.
- BCS Class III non-HVDs are 27% of drugs, with HVDs at 3%.
- Biowaivers for Class I drugs could save $66-$76 million annually, with $21-$24 million from HVDs. Extending to Class III could add $62-$71 million, including $9-$10 million from HVDs.
Conclusions:
- BCS-based biowaivers for Class I drugs offer significant annual cost savings.
- Expanding biowaivers to BCS Class III drugs presents a substantial opportunity for further economic benefits.
- The inclusion of HVDs highlights specific areas where biowaivers can maximize cost efficiencies in drug development.
More Related Videos
Related Concept Videos
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:28Biopharmaceutics and Pharmacokinetics: Overview
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the appropriate...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
01:16Bioequivalence: Overview
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...